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D E V E L O P M E N T A L  N E U R O S C I E N C E
The CHD8/CHD7/Kismet family links blood-brain barrier 
glia and serotonin to ASD-associated sleep defects
Mireia Coll-Tané1*, Naihua N. Gong2, Samuel J. Belfer2, Lara V. van Renssen1, Evangeline C. Kurtz-Nelson3, 
Milan Szuperak2, Ilse Eidhof1, Boyd van Reijmersdal1, Isabel Terwindt1, Jaclyn Durkin2,  
Michel M. M. Verheij4, Chang N. Kim5, Caitlin M. Hudac6, Tomasz J. Nowakowski5,  
Raphael A. Bernier3, Sigrid Pillen7, Rachel K. Earl3, Evan E. Eichler8,9, Tjitske Kleefstra1,  
Matthew S. Kayser2, Annette Schenck1*
Sleep disturbances in autism and neurodevelopmental disorders are common and adversely affect patient’s 
quality of life, yet the underlying mechanisms are understudied. We found that individuals with mutations in 
CHD8, among the highest-confidence autism risk genes, or CHD7 suffer from disturbed sleep maintenance. These 
defects are recapitulated in Drosophila mutants affecting kismet, the sole CHD8/CHD7 ortholog. We show that 
Kismet is required in glia for early developmental and adult sleep architecture. This role localizes to subperineu-
rial glia constituting the blood-brain barrier. We demonstrate that Kismet-related sleep disturbances are caused 
by high serotonin during development, paralleling a well-established but genetically unsolved autism endophe-
notype. Despite their developmental origin, Kismet’s sleep architecture defects can be reversed in adulthood by 
a behavioral regime resembling human sleep restriction therapy. Our findings provide fundamental insights into 
glial regulation of sleep and propose a causal mechanistic link between the CHD8/CHD7/Kismet family, develop-
mental hyperserotonemia, and autism-associated sleep disturbances.
INTRODUCTION
Sleep is essential for health and cognition. In neurodevelopmental 
disorders, sleep disturbances are among the most common co- 
occurring features, observed with an incidence ranging between 50 
and 80% (compared to ~20% in typically developing children) (1, 2). 
Sleep problems adversely affect quality of life in patients and their 
families, to an extent that can exceed the burden of other physical 
and cognitive deficits (1, 3). Despite evidence that sleep interventions 
can improve behavioral and cognitive outcomes (4), the mechanisms 
underlying sleep disturbances in the context of these disorders are 
unclear and understudied.
We propose that monogenic (Mendelian) neurodevelopmental 
syndromes that are characterized by highly prevalent and specific 
sleep disturbances offer unique opportunities to investigate disease 
pathologies and mechanisms, including those underlying sleep dif-
ficulties. At the same time, this work holds the potential to provide 
novel fundamental insights into the biology of sleep and its mecha-
nistic links to cognitive disorders.
Pathogenic mutations in the CHD8 (chromodomain helicase 
DNA binding protein 8) gene are a leading risk factor for autism 
spectrum disorders (ASDs) and among the most frequent findings 
revealed by large-scale exome sequencing efforts (5–7). They define 
an ASD subtype with distinctive clinical features [Online Mendelian 
Inheritance in Man (OMIM) 615032], including sleep complaints 
in most individuals with CHD8 mutations, while other clinical co-
morbidities such as intellectual disability (ID) remain variable (5, 8). 
However, the nature of CHD8-associated sleep problems (i.e., which 
parameters of sleep are affected) is unclear, and whether CHD8 mu-
tations increase the risk of sleep complaints compared to other genetic 
forms of ASD is controversial (9). Disruptive de novo mutations in 
the CHD8 paralog CHD7 lead to CHARGE syndrome (OMIM 214800), 
a rare and phenotypically variable neurodevelopmental disorder 
characterized predominantly by severe ID (10, 11). Although initially 
less attention has been paid to behavioral problems, it is now well es-
tablished that children with CHARGE syndrome also frequently ex-
hibit autistic features and sleep disturbances (12,  13). In these 
patients, sleep problems are significantly associated with anxiety 
and autistic-like behaviors, greatly influencing their quality of life 
(12). CHD8 and CHD7 interact with each other and are part of a 
large multisubunit complex that organizes chromatin assembly (14). 
Their molecular interaction suggests that the overlapping clinical fea-
tures of both disorders have a common mechanistic basis.
Work in Drosophila melanogaster, the fruit fly, has made seminal 
contributions to our understanding of sleep and neurodevelopmen-
tal disorders (15, 16). In Drosophila, kismet (kis) is the sole ortholog 
of CHD8 and CHD7 (17). Neuronal Kismet regulates morphology 
and synaptic physiology of the larval neuromuscular junction, axo-
nal morphology and pruning of Kenyon cells, memory, and motor 
function (17–19). Moreover, Kismet is essential in a subset of circa-
dian neurons for light-dependent circadian responses (20).
Here, we analyzed the role of the CHD8/CHD7/Kismet family in 
sleep regulation across species. First, we characterized the nature of 
sleep complaints in individuals with CHD8 and CHD7 mutations. 
We found specific defects in sleep initiation and maintenance that 
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are highly consistent with each other and closely recapitulated in 
Drosophila. Leveraging the genetic tractability of Drosophila, we in-
vestigated the underlying spatiotemporal mechanisms of these sleep 
disturbances. Our data demonstrate that Kismet is required in glia, 
not in neurons, for sleep integrity at both larval and adult stages. 
We further localize sleep disturbances to a glial subtype constituting 
the blood-brain barrier (BBB) and to high serotonin levels during 
development, linking several previously unconnected dots in autism 
pathology. Last, despite the developmental origin of Kismet sleep 
defects, we provide a translatable behavioral strategy to ameliorate 
adult sleep abnormalities.
RESULTS
Individuals with mutations in CHD8 and CHD7 suffer 
from sleep initiation and maintenance defects
Previous studies suggest a high prevalence of sleep complaints in 
individuals with mutations in CHD8 (5, 9). A more detailed exam-
ination of sleep disturbances in this population has not been de-
scribed. We extracted detailed sleep data from 23 individuals with 
disruptive CHD8 variants from the Simons Simplex Collection (SSC) 
and National Institute of Mental Health-funded TIGER study, two 
large studies of neurodevelopmental disorder cohorts characterized 
by rare, ASD-associated single gene etiologies. This cohort showed 
significantly higher rates of difficulties falling asleep and maintain-
ing asleep (i.e., frequent or prolonged nighttime awakenings) 
compared to a large sample of SSC individuals with idiopathic 
ASD (Fig. 1A and table S1). In addition, we observed a higher fre-
quency of daytime complaints; however, this tendency did not 
withstand correction for multiple testing. There was no significant 
difference in rates of other sleep difficulties between groups.
Next, we further pursued in-depth sleep phenotyping in a small 
cohort consisting of one individual with a CHD8 (individual 01) and 
three with CHD7 mutations (individuals 02 to 04). All four individuals 
presented with sleep initiation and maintenance problems as indi-
cated by increased sleep onset latency (SOL), increased wake after 
sleep onset (WASO), decreased sleep efficiency (SE; proportion of 
time spent asleep while lying in bed), and shorter total sleep time 
(TST) compared to reference values. Hence, all individuals exhibited 
chronic insomnia disorder as defined by the ICSD (International 
Classification of Sleep Disorders)–3 criteria (Table 1). Notably, 
except in one individual with a sleep-related rhythmic movement dis-
order, a common finding in children, no other sleep disorders [e.g., 
obstructive sleep apnea, as previously reported in some individuals 
with CHARGE syndrome (21)] were present. Objective measures of 
sleep, polysomnography (PSG) or actigraphy, were collected in in-
dividuals 02 and 04, respectively (fig. S1), validating the results of the 
sleep diaries. Our results are also consistent with previously reported 
sleep initiation and maintenance problems in CHARGE syndrome 
based on questionnaires, albeit these were collected, in part, for in-
dividuals lacking a genetic diagnosis (3,  13). Together, our data 
strongly suggest a specific role for both CHD8 and CHD7 in sleep 
initiation and maintenance.
Kismet mutants recapitulate human sleep 
maintenance defects
To address the potential role of the Drosophila CHD8/CHD7 ortho-
log Kismet (Fig. 1B) in sleep, we first set out to characterize sleep in 
kisk13416 mutants. While homozygous kisk13416 flies are not viable, 
kisk13416/+ flies showed a mild but significant decrease in TST both 
during the light and dark periods (Fig. 1C). To allow for comparison 
with human sleep measures, we assessed orthologous sleep metrics 
(22) and found SE to be decreased (Fig. 1D). Whereas sleep latency 
was unaffected (Fig. 1E), mutants spent more time awake at night 
after their first sleep episode (WASO) (Fig. 1F). The elevated WASO 
Fig. 1. Mutations in the conserved CHD8/7/kismet family leads to sleep distur-
bances. (A) Individuals with disruptive CHD8 mutations present with higher rates 
of difficulties falling asleep and frequent/prolonged night awakenings compared 
to a SSC idiopathic ASD cohort. Groups were compared using Fisher’s exact tests. 
Bonferroni correction for multiple comparisons was applied to the significance lev-
el (P < 0.005). Values in bold withstand correction for multiple testing. (B) High con-
servation of protein domains between human CHD8 and CHD7 and Drosophila 
Kismet. Percentages indicate similarity of amino acid sequence between Kismet 
and CHD8 (top) or CHD7 (bottom). CHROMO, chromatin organization modifier. 
(C) Sleep profile and quantification of TST of kisk13416/+ flies (n = 55) and iso31 genetic 
background controls (n = 61). kisk13416/+ mutants show decreased TST during the 
light period [LP; Zeitgeber time (ZT) 0 to ZT12, P = 0.016, t = 3.244, df = 96.44] and 
dark period (DP; ZT12 to ZT24, P < 0.0001, t = 5.201, df = 87.4). (D) SE is reduced in 
kisk13416/+ (P < 0.0001, t = 5.201, df = 87.4). (E) Latency to the first sleep bout after 
lights-on or lights-off is unaffected (P > 0.8). (F) WASO is increased at night (P < 0.0001, 
t = 5.2, df = 88.14). (G) Average bout duration in kisk13416/+ flies is strongly reduced 
specifically during the DP (P < 0.0001, t = 4.781, df = 68.78), while (H) the number of 
bouts is increased (P < 0.0001, t = 1.039, df = 111.1). (I) P(Wake) is significantly in-
creased during the DP (P = 0.0048, t = 3.442, df = 48.07), while (J) P(Doze) is decreased in 
LP (P = 0.0075, t = 3.255, df = 59.37) but increased in DP (P = 0.042, t = 2.692, df = 36.62) 
in kisk13416/+ mutants compared to iso31. Data are represented as means ± SEM. 
Two-tailed unpaired Welch’s t test with Bonferroni correction for multiple testing. 
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in these animals was due to fragmented nighttime sleep, with a strong 
reduction in average sleep bout duration (from 140 min in controls to 
61 min in kisk13416/+) and an increase in the number sleep bouts (Fig. 1, 
G and H), revealing altered sleep architecture. We assessed circadian 
rhythms of locomotor activity in kismet mutants by means of fast 
Fourier transform (FFT). They showed normal rhythmicity (fig. S2).
We further determined two recently defined conditional proba-
bilities to measure Drosophila sleep depth and pressure (23); P(Wake) 
can be regarded as a behavioral correlate of sleep depth or arousal, 
whereas P(Doze) reflects sleep pressure. kisk13416/+ mutants showed 
elevated P(Wake) and P(Doze) at night, suggesting that sleep-wake 
instability drives nighttime sleep fragmentation (Fig.  1,  I  and  J). 
P(Doze) was also decreased during the day, indicating reduced sleep 
drive during this time. Together, kismet mutant flies show reduced 
sleep duration with altered sleep architecture, indicating defects in 
sleep maintenance. These sleep deficits resemble the identified sleep 
disturbances in individuals with CHD8/7 mutations.
Kismet is required in glia for sleep integrity
To collect independent evidence for the role of Kismet in sleep in-
tegrity and to identify the cellular substrates through which it exerts 
its function, we next knocked down its expression in various cell 
types using the UAS-Gal4 system and inducible RNA interference 
(RNAi). Unexpectedly, kismet knockdown with the pan-neuronal 
elav-Gal4 did not recapitulate kisk13416/+ sleep defects (fig. S3, A to 
C). In contrast, pan-glial expression of two nonoverlapping RNAi 
constructs, UAS-kisRNAi-1 and UAS-kisRNAi-2, both gave rise to a sig-
nificant reduction in TST at night (Fig. 2, A and B). This loss was due 
to a markedly decreased mean sleep bout duration (Fig. 2, Ai and Bi), 
partially compensated by an increase in the number of sleep bouts 
(Fig. 2, Aii and Bii). Thus, pan-glial knockdown recapitulated the 
reduced and fragmented nighttime sleep, causing even more severe 
defects than shown by the heterozygous kismet mutants. This indi-
cates that Kismet is required in glia for sleep integrity.
Adult sleep integrity relies on Kismet during development
To investigate whether Kismet is required in glia for sleep integrity 
during development or acutely in adulthood, we used temporal and 
regional gene expression targeting (TARGET) to restrict kismet 
knockdown to either before or after eclosion (Fig. 2, C and D). Flies 
carrying the repo-Gal4 driver and ubiquitous GAL4 repressor tub-
Gal80ts kept at restrictive temperature (22°C, knockdown OFF) 
throughout their life span showed comparable TST and architec-
ture to background controls (fig. S4, A, Ai, and Aii). In contrast, 
when kept at the permissive temperature (28°C, knockdown ON), 
flies exhibited decreased and fragmented nighttime sleep (fig. S4, B, 
Bi, and Bii). Pan-glial kismet knockdown confined to pre-eclosion 
stages with either UAS-kisRNAi line resulted in decreased and frag-
mented nighttime sleep in the adult, recapitulating the defects in 
kismet knockdown throughout life span (Fig. 2, E, Ei, and Eii, and 
fig. S4, C, Ci, and Cii). In contrast, kismet knockdown exclusively in 
adult glia did neither alter sleep quantity nor architecture (Fig. 2, 
F, Fi, and Fii, and fig. S4, D, Di, and Dii). Together, these results 
demonstrate that Kismet is required during pre-eclosion develop-
mental stages in glia for adult sleep integrity.
Kismet is required in subperineurial glia of the BBB 
for sleep integrity
We next asked whether Kismet acts in neuropil-associated glia 
[astrocyte-like glia (ALG) and ensheathing glia (EG)], cortex glia (CG), 
or surface glia [perineurial glia (PG) and subperineurial glia (SPG)]. 
While previous work has implicated almost all glia subtypes in sleep 
Table 1. One individual with a CHD8 (01) and three individuals with CHD7 (02 to 04) pathogenic mutations, seen at a sleep clinic, also reported 
difficulties falling asleep and night awakenings. Quantitative sleep parameters from parent-reported sleep-wake diaries confirmed these complaints: SOL 
and WASO were increased, and SE was decreased. Values in bold are deviating from established healthy reference values (68, 79, 80). See also Fig. 1, fig. S1, and 
tables S1 and S2. 
Individuals 01 02 03 04
Gender Male Female Female Female
Age of examination (years) 4 3 8 19
Molecular diagnosis
CHD8 CHD7 CHD7 CHD7
c.4062 + 5G > C c.4493_4506del c.2643 T > A c.5181 > G
p.(Ser1350fs) p.(lle1498fs) p.(Tyr881*) p.(Tyr1727*)
Main sleep complaints
Difficulty falling asleep Difficulty falling asleep Difficulty falling asleep Difficulty falling asleep
Night awakenings Night awakenings Night awakenings Night awakenings





Days measured 14 14 7 16
TIB (min) 715.7 677.1 762.9 647.8
Total sleep time (min) 474.6 559.3 514.3 400.3
SOL (min) 0 20.4 160.7 197.8
WASO (min) 241.1 97.5 87.9 49.7
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regulation (24–26), sleep loss and fragmentation have exclusively 
been linked to ALG (27, 28). Using specific Gal4 drivers (29, 30), we 
noted that kismet knockdown in ALG (NP3233-Gal4) showed mild 
sleep fragmentation during both day and night (fig. S5, A, Ai, and 
Aii). Knockdown in EG (NP6520-Gal4) or CG (NP2222-Gal4) did 
not cause nighttime sleep fragmentation (fig. S5, B, Bi, Bii, C, 
Ci, and Cii).
Notably, kismet knockdown using the well-characterized 
R54C07-Gal4 driver targeting SPG presented with the combination 
of decreased nighttime sleep time and reduction of average sleep 
bouts observed in kisk13416/+ and pan-glial knockdown, with both 
UAS-kisRNAi lines (Fig. 3, A, Ai, Aii, B, Bi, and Bii). Furthermore, 
kismet knockdown with an independent SPG driver line (NP2276-Gal4) 
resulted in decreased total sleep and bout duration and increased 
Fig. 2. Pan-glial kismet knockdown leads to decreased and fragmented nighttime sleep, a phenotype of developmental origin. (A, B, E, and F) Sleep profiles and/
or quantification. (Ai, Bi, Ei, and Fi) Average duration and (Aii, Bii, Eii, and Fii) number of sleep bouts during the LP (ZT0 to ZT12) and DP (ZT12 to ZT24). (A, Ai, and Aii) 
Pan-glial kismet knockdown flies (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-1, in turquois, n = 65) compared to background controls (repo-Gal4,UAS-Dcr2/+ in black, n = 74; UAS- 
kisRNAi-1/+ in gray, n = 61) show reduced sleep time (P < 0.0001) and sleep fragmentation, characterized by reduced bout length (P < 0.0001), accompanied by increased bout 
number (P < 0.0001 and P = 0.011, respectively) exclusively during DP. (B, Bi, and Bii) Pan-glial kismet knockdown (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-2, in turquois, n = 77) 
compared to background (repo-Gal4,UAS-Dcr2/+ in black, n = 90; UAS-kisRNAi-2/+ in dark gray, n = 65) and UAS-40D controls (repo-Gal4,UAS-Dcr2 > UAS-40D, in light gray, 
n = 67), causes reduced sleep time (P < 0.0001) and reduced bout length (P < 0.0001), accompanied by increased bout number (P = 0.0027 and P < 0.0001, respectively), 
during DP. (C) Schematic representation of the TARGET system and (D) performed temperature shifts to achieve pre- and posteclosion knockdown. (E, Ei, and Eii) Pre-eclosion 
pan-glial kismet knockdown (repo-Gal4,tubGal80ts > UAS-kisRNAi-2, in blue, n = 44) show decreased and fragmented sleep (P = 0.0006, P = 0.0003, and P = 0.006, respectively) 
during DP compared to controls (repo-Gal4,tubGal80ts/+, in black, n = 31). (F, Fi, and Fii) Posteclosion pan-glial kismet knockdown (repo-Gal4,tubGal80ts > UAS-kisRNAi-2, in 
blue, n = 51) does not alter sleep compared to controls (repo-Gal4,tubGal80ts/+, in black, n = 34). Data are represented as means ± SEM. (A, Ai, Aii, B, Bi, and Bii): Kruskal-Wallis test 
with Dunn’s correction. (E, Ei, Eii, F, Fi, and Fii): Two-tailed unpaired Welch’s t test. Bonferroni correction for multiple testing. P values are indicated as follows: *P < 0.05, 
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bout number (fig. S5, E, Ei, and Eii). SPG are a group of about 300 
cells that, together with the PG, form the Drosophila BBB (29). The 
inner SPG layer forms the paracellular barrier that separates the 
brain from the hemolymph, whereas PG provide physical and met-
abolic support and harbor a peripheral molecular clock that modu-
lates circadian changes in BBB permeability (31). However, we found 
that kismet knockdown in PG (R85G01-Gal4) did not alter night-
time sleep (Fig. 3, C, Ci, and Cii). It has also been shown that inhi-
bition of endocytosis of the surface glia increases baseline sleep and 
induces resistance to mechanical sleep deprivation (26). In contrast, SPG 
kismet knockdown did not affect homeostatic sleep rebound after 
mechanical deprivation (fig. S6, A and B). Together, these findings 
demonstrate that loss of kismet in SPG underlies reduced sleep and 
severe sleep fragmentation.
Loss of Kismet in SPG disrupts sleep architecture 
in developing larvae
Given that kismet knockdown in glia before eclosion is sufficient to 
alter sleep architecture in the adult fly, we wondered whether sleep 
problems may already manifest during development. Second instar 
Fig. 3. Kismet function in sleep integrity maps to SPG of the BBB. (A) Schematic representation of glia subtypes in the adult Drosophila brain. (B to D) Sleep profiles 
and quantification. (Bi, Ci, and Di) Average duration and (Bi, Ci, and Di) number of sleep bouts in the LP (ZT0 to ZT12) and DP (ZT12 to ZT24). (B, Bi, and Bii) Kismet knock-
down in SPG with the R54C07-Gal4 driver (SPG-Gal4 > UAS-kisRNAi-1, in orange, n = 104) compared to background controls (SPG-Gal4/+, in black, n = 134; UAS-kisRNAi-1/+ in 
gray, n = 85) shows reduced sleep time during both LP (P = 0.0006) and DP (P < 0.0001), due to shorter sleep bouts (P < 0.0001). (C, Ci, and Cii) Kismet knockdown in SPG 
with the R54C07-Gal4 driver (SPG-Gal4 > UAS-kisRNAi-2, in orange, n = 108) compared to background controls (SPG-Gal4/+, in black, n = 150; UAS-kisRNAi-2/+ in dark gray, 
n = 86) and UAS-40D control (SPG-Gal4 > UAS-40D, in light gray, n = 66) shows reduced sleep time during DP (P < 0.0001). Knockdown flies also display shorter nighttime 
bouts (P < 0.0001) accompanied by an increase in their number (P < 0.0001 and P = 0.0024, respectively). (D, Di, and Dii) Kismet knockdown in PG with the R85G01-Gal4 
driver (PG-Gal4 > UAS-kisRNAi-1, in red, n = 80) compared to background controls (PG-Gal4/+ controls in black, n = 84; UAS-kisRNAi-1/+ in gray, n = 62) shows reduced sleep 
time at LP (P = 0.013 and P < 0.0001, respectively). Nighttime sleep is unaffected. Data are represented as means ± SEM. Kruskal-Wallis test with Dunn’s correction. Bonfer-
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Drosophila larvae have recently been shown to exhibit quiescent pe-
riods that meet the behavioral criteria of sleep (32). Kismet knock-
down in SPG did not alter the total amount of larval sleep (Fig. 4A) 
but disrupted sleep architecture, resulting in decreased bout length 
(Fig. 4Ai) accompanied by an increase in bout number (Fig. 4Aii). 
As observed for adult sleep, larval sleep remained unaffected by 
kismet knockdown in PG (Fig. 4, B, Bi, and Bii). Together, Kismet is 
required in second instar larvae for proper sleep architecture, and 
this role too localizes to SPG.
Glial Kismet loss leads to hyperserotonemia
To shed light onto the mechanisms by which loss of Kismet affects 
sleep, we first considered whether established sleep regulatory mech-
anisms may mediate Kismet function. Extensive research has high-
lighted the crucial role of dopamine in sleep and arousal and how 
dysfunctions of the dopaminergic system can lead to reduced and 
fragmented sleep (33). Therefore, we performed high-performance 
liquid chromatography (HPLC) to measure dopamine, using a column 
that simultaneously allowed us to assess serotonin (5-hydroxytryptamine) 
levels. Fly heads from pan-glial kismet knockdown and controls were 
collected at Zeitgeber time 6 (ZT6) and 18 (ZT18), without disturb-
ing the light:dark (LD) cycle. Dopamine levels at ZT6 were unal-
tered, whereas we observed a significant, although mild, decrease of 
total dopamine levels at nighttime (ZT18) (Fig. 5A). In contrast, 
serotonin showed a notable 2-fold (ZT6) and 2.4-fold (ZT18) increase 
(Fig. 5B).
Following up on this finding, we investigated serotonin levels 
during development. We performed antiserotonin fluorescence 
immunohistochemistry and quantitative imaging (via photon 
counting, see Materials and Methods), in pan-glial and SPG-specific 
kismet knockdown wandering third instar larvae. We focused on 
the projections of serotonergic neurons of the subesophagal gan-
glion that innervate the proventriculus and anterior midgut of the 
larval digestive tract (Fig. 5C) (34). In controls, serotonin was visible 
in the proventricular nerve and at the level of proventricular inner-
vations but absent or hard to discern in the distal projections that 
innervate the anterior midgut. In contrast, loss of glial Kismet led to 
elevated serotonin signal (Fig. 5D and fig. S7A), with serotonergic 
midgut innervations strongly labeled. As the innervated tissues ap-
peared to show slightly higher levels of staining too, we quantified 
total signal intensities of -serotonin signal across the proventric-
ulus and in the anterior midgut, containing both the serotonergic 
terminals and the innervated tissues. We observed significantly in-
creased serotonin at the midgut region of pan-glial kismet knock-
down larvae (fig. S7, B, Bi, Bii, C, Ci, and Cii). Similarly, serotonin 
was significantly increased at the level of the proventriculus and 
midgut of SPG-specific kismet knockdown larvae (Fig. 5Di and fig. 
S7, E and Ei). Together, these results demonstrate that Kismet loss 
in glia leads to increased serotonin during development. The finding 
that glial loss of Kismet leads to increased serotonin is of considerable 
interest, as elevated serotonin (hyperserotonemia) is one of the most 
replicated, yet genetically unsolved, biomarkers in ASD (35, 36).
Developmental hyperserotonemia underlies Kismet’s 
glia-dependent sleep defects
To investigate whether restoring dopamine signaling can reverse the 
sleep defects of pan-glial kismet knockdown, we supplemented the 
food with methylphenidate (MPH; 1 mg/ml a dopamine transporter 
blocker that increases extracellular dopamine levels by blocking its 
reuptake), a dose that we and others has previously been shown to 
rescue sleep and other behavioral deficits of dopamine-related mutant 
conditions (33, 37). However, MPH did not rescue sleep duration or 
architecture in the setting of kismet knockdown (fig. S8, A, Ai, and Aii).
Next, we addressed the hypothesis that the observed high 
serotonin levels underlie the reduced and fragmented sleep in the 
setting of glial kismet knockdown, by testing the effect of phar-
macological serotonin depletion. Adult administration of 20 mM 
-methyl-dl-tryptophan (MTP), a specific Trh (CG9122) inhibitor 
(Fig. 5E) that has been show to induce a ~2-fold decrease in sero-
tonin levels in fly heads (38), failed to improve sleep deficits of kismet 
pan-glial knockdown (Fig. 5, F and Fi). Administration of the same 
dose throughout development led to high lethality in control flies 
but notably allowed pan-glial kismet knockdown flies to survive. 
In this population, MTP supplementation fully averted the adult 
sleep fragmentation (Fig. 5, F and Fi). Thus, elevated serotonin levels 
during development underlie, at least partially, the sleep fragmenta-
tion observed in adult kismet pan-glial knockdown flies.
Next, we sought to determine whether increased serotonin levels 
are sufficient to induce decreased and fragmented sleep. First, we 
attempted to pharmacologically increase serotonin levels by feeding 
its precursor 5-hydroxytryptophan (5-HTP; Fig. 5E). Administration 
of 5 mM 5-HTP specifically during development led to decreased 
sleep time and shorter sleep bouts in adults (Fig. 5, G and Gi). Second, 
recent work has shown that acute opto- or thermogenetic activation 
of serotonergic neurons in Drosophila adults leads to a decrease in 
sleep bout length and increase in sleep bout number, indicating that 
increased release of serotonin can fragment sleep (39). As Kismet’s 
Fig. 4. Loss of Kismet in SPG leads to fragmented sleep in the larval stage. 
Kismet knockdown in SPG with the R54C07-Gal4 driver (SPG-Gal4 > UAS-kisRNAi-2, in 
orange, n = 20) compared to background controls (SPG-Gal4/+, in black, n = 19) 
does not alter the (A) total amount of larval (second instar) sleep (quiescence 
bouts) (P = 0.7, t = 1.149, df = 36.78) but causes (Ai) decreased duration (P = 0.003, 
t = 3.585, df = 36.98) and (Aii) increased number (P = 0.0003, t = 4.32, df = 35.14) of 
sleep bouts. (B) Kismet knockdown in PG with the R85G01-Gal4 driver (PG-Gal4 > 
UAS-kisRNAi-2, in red, n = 17) compared to background controls (PG-Gal4/+, in black, 
n = 13) does not alter the total amount of larval (second instar) sleep (P > 0.9, 
t = 0.178, df = 26.72), (Bi) average sleep bout duration (P > 0.9, t = 0.0186, df = 20.04) 
and (Bii) number (P = 0.7, t = 1.183, df = 25.44). Data are represented as means ± SEM. Two-
tailed unpaired Welch’s t test with Bonferroni correction for multiple testing. P values 
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sleep phenotype is due to increased serotonin during development, 
we evaluated the effect of activating serotonergic neurons at this time. 
We expressed the heat-activated channel dTrpA1 using the Trh-Gal4 
driver and activated these neurons by raising the temperature while 
monitoring sleep in second instar larvae (Fig. 5H). Activation of 
serotonergic neurons with two different drivers led to a large reduc-
tion in sleep bout length and total sleep amount (Fig. 5, I, Ii, and Iii, 
and fig. S8, B, Bi, and Bii).
Last, we increased serotonin by reducing its metabolization. Serotonin 
acetylation, catalyzed by the arylalkylamine N-acetyltransferase 1 
Fig. 5. Sleep defects upon glial kismet loss are caused by developmental hyperserotonemia. (A and B) repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-1 (blue, n = 6 to 7) exhibit de-
creased dopamine at ZT18 (P = 0.0028) and ≥2-fold increased serotonin at ZT6 (P = 0.0077) and ZT18 (P = 0.0004) compared to controls (black, n = 7). (C) Scheme of the larval 
digestive tract and serotonergic innervations. (D) Representative images and (Di) quantification of -serotonin immunolabeling. SPG kismet knockdown (R54C07-
Gal4 > UAS-kisRNAi-1, orange, n = 8) causes increased serotonin in distal innervations (arrowheads) and diffuses signal in the proventriculus (P = 0.037) and anterior midgut 
(P = 0.0002) compared to controls (black, n = 8). Scale bars, 50 m. (E) Serotonin metabolism in Drosophila and used approaches to manipulating it. (F, G, and J) Sleep profiles 
and/or quantification. (Fi, Gi, and Ji) Average duration and (Jii) number of sleep bouts during LP (ZT0 to ZT12) and DP (ZT12 to ZT24). (F and Fi) Pan-glial knockdown (repo-
Gal4,UAS-Dcr2 > UAS-kisRNAi-1, dark blue, n = 32) fed with MTP during development (light blue, n = 49), but not adulthood (light blue dotted, n = 30), shows restored TST and 
sleep bout duration to vehicle-reared controls (black, n = 41). (G and Gi) Increasing serotonin in wild type (hatched black, n = 72) by developmental 5-hydroxytryptophan 
(5-HTP) feeding leads to decreased sleep due to significantly reduced sleep bout length compared to vehicle-fed animals (black, n = 70), phenocopying kismet 
knockdown (blue, n = 62). (H) Temperature program for thermogenetically controlled larval sleep recordings: (I to Iii) Thermogenetic activation of serotonergic neurons 
[Trh-Gal4(II) > UAS-dTrpA1, green, n = 37] leads to decreased sleep amount (P < 0.0001), bout length (P < 0.0001), and number (P = 0.035 and P = 0.02, respectively) compared 
to parental controls (Trh-Gal4(II)/+, n = 29; UAS-dTripA1/+, n = 28). (J to Jii) SPG AANAT1 knockdown (SPG-Gal4 > UAS-AANAT1RNAi-1, n = 97) leads to decreased total sleep 
(P < 0.0001) and bout length (P < 0.0001) compared to controls (SPG-Gal4/+, n = 125; UAS-AANAT1RNAi-1/+, n = 37). Data are represented as means ± SEM, except (Di) 
represented as means ± 95% confidence interval. (A, B, and Di): Two-tailed unpaired Welch’s t test. (F, Fi, G, Gi, H, I, Ii, and Iii): Kruskal-Wallis test with Dunn’s correction. (J, Ji, and 
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(AANAT1) enzyme (Fig. 5E), is the main mechanism of neurotrans-
mitter inactivation in Drosophila, which stands in contrast to mam-
mals where oxidation plays a central role (40). We therefore knocked 
down AANAT1 in all glia and in SPG. Whereas pan-glial AANAT1RNAi-1 
knockdown was lethal, AANAT1 knockdown with a second RNAi 
line (AANAT1RNAi-2) resulted in fragmented nighttime sleep (fig. S8, 
C, Ci, and Cii). Moreover, AANAT1RNAi-1 induction in SPG was viable 
and phenocopied the reduced and fragmented nighttime sleep 
(Fig. 5, J, Ji, and Jii). The latter finding was replicated with a third indepen-
dent RNAi line targeting AANAT1 (UAS-AANAT1RNAi-3) (fig. S8, D, Di, 
and Dii). Together, our data provide strong evidence for loss of glial 
Kismet causing sleep loss and fragmentation through increased 
serotonin levels during development.
Sleep restriction therapy restores sleep architecture in glial 
Kismet models
We aimed to identify approaches to improving sleep quality in our 
preclinical Kismet models. Approaches suitable for direct transla-
tion into the clinic should (i) require only postdevelopmental 
intervention and (ii) should be noninvasive and nonhazardous. 
Human sleep restriction therapy (SRT) is a key component of cognitive 
behavioral therapy for insomnia (CBT-I), the first-line intervention 
to treat chronic insomnia in humans (41). By restricting the sleep 
opportunity window, SRT enhances sleep drive leading to a more 
efficient and consolidated sleep. We recently established a model 
for SRT in flies and demonstrated that SRT in flies improves SE and 
continuity in short-sleeping Drosophila mutants and a fly model for 
Alzheimer’s disease (22). Whether SRT can reverse sleep defects in 
neurodevelopmental disorders models is unknown.
We first restricted sleep opportunity in pan-glial kismet knockdown 
flies by reducing dark period duration. An SRT regime of 14:10 LD 
did not increase TST compared with pan-glial or SPG kismet knockdown 
flies in 12:12 LD (fig. S9, A and Ai); however, SE was fully rescued to 
control levels (Fig. 6, A, Ai, B, and Bi). Furthermore, SRT rescued 
sleep bout duration (Fig. 6, C and Ci) and bout number (Fig. 6, D 
and Di). Most notably, both pan-glial and SPG kismet knockdown 
flies showed a significant decrease in WASO, back to control at 12:12 
LD levels (Fig. 6, E and Ei). SRT further reduced latency to sleep at 
night compared to flies in a 12:12 LD regime (fig. S9, B and Bi). 
Together, our data show that a behavioral regime can rescue sleep 
defects of Kismet models despite their developmental origin, includ-
ing disturbed sleep architecture, decreased efficiency and increased 
WASO, The critical sleep metrics affected in individuals with CHD8 
and CHD7 mutations.
Fig. 6. Sleep restriction therapy rescues sleep architecture in Drosophila glia Kismet models. (A) Representative sleep profiles of pan-glial kismet knockdown flies 
entrained either at 12:12 LD (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-2, in dark blue, n = 13) or at 14:10 LD (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-2, in light blue, shortened DP ZT14 to 
ZT24, n = 15). (Ai) Representative sleep profiles of SPG kismet knockdown flies entrain either at 12:12 LD (SPG-Gal4 > UAS-kisRNAi-2, in dark orange, n = 16) or at 14:10 LD 
(SPG-Gal4 > UAS-kisRNAi-2, in light orange, n = 16). (B to E) Quantification of sleep parameters of control flies entrained at 12:12 LD (repo-Gal4,UAS-Dcr2/+, in gray, n = 61), 
and pan-glial kismet knockdown flies entrain either at 12:12 LD (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-2, in dark blue, n = 62) or at 14:10 LD (repo-Gal4,UAS-Dcr2 > UAS-kisRNAi-2, 
in light blue, n = 63). (Bi, Ci, Di, and Ei) Quantification of sleep parameters of control flies entrained at 12:12 LD (SPG-Gal4/+, in gray, n = 85), and SPG kismet knockdown 
flies entrain either at 12:12 LD (SPG-Gal4 > UAS-kisRNAi-2, in dark orange, n = 97) or at 14:10 LD (SPG-Gal4 > UAS-kisRNAi-2, in light orange, n = 100). (B and Bi) SE, (C and Ci) 
average duration, and (D and Di) number of sleep bouts in the DP. (E and Ei) WASO; minutes spent awake after first sleep episode during DP. SRT successfully improves SE 
and architecture in pan-glial and SPG kismet knockdown flies. Data are represented as a boxplot that extends from the 25th to the 75th percentiles with the median indi-
cated. Whiskers indicate the 5th and 95th percentiles. Kruskal-Wallis test with Dunn’s correction. Bonferroni correction for multiple testing. P values are indicated as fol-
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Human CHD8 and CHD7 are expressed in glia 
and components of the BBB
Last, to address whether a conserved role in glia or other cells form-
ing the BBB can underlie the sleep disturbances shared by Drosophila 
Kismet mutants and individuals with mutations in CHD8 or CHD7, 
we revisited recent high-resolution single-cell RNA sequencing 
(RNA-seq) datasets of human cortex at prenatal and postnatal stag-
es. We found CHD8 and CHD7 to be modestly to highly expressed 
in all cells forming the human BBB, both during development (ra-
dial glia, astrocytes, endothelial, and mural cells) and in adulthood 
(astrocytes, endothelial cells, and pericytes) (Fig. 7, A, Ai, and Aii). 
At adult stage, CHD7 shows a notable enrichment in glia compared 
to neuronal populations, whereas CHD8 is widely expressed across 
the brain (Fig. 7, B, Bi, and Bii). In conclusion, cutting edge single- 
cell data support a role for both kismet orthologs in glia and other 
cell types constituting the human BBB, both during development 
and in adulthood.
DISCUSSION
Sleep problems in ASD-associated neurodevelopmental syndromes 
and idiopathic ASD are a common complaint. The negative impact 
of sleep loss on these vulnerable patient groups and their families 
is particularly high, and therapeutic options are urgently needed. 
Whether sleep is under direct control of genes implicated in ASD 
and related neurodevelopmental disorders is unknown for the vast 
majority of disorders. Motivated by reports on frequent and severe 
sleep disturbances in individuals with mutations in the chromatin 
remodeler CHD8 and its paralog CHD7, we here characterized in-
depth their sleep deficits and dissected the underlying mechanisms 
using Drosophila as a model. Our study provides previously un-
known fundamental insights into the regulation of sleep, linking 
autism-related CHD8 and CHD7 genes, BBB glia, and developmental 
hyperserotonemia with sleep maintenance defects, and identifies 
a safe, validated, and translatable behavioral strategy to reduce sleep 
challenges for patients.
Specific and highly conserved sleep deficits caused by 
mutations in the CHD8/CHD7/Kismet chromatin 
remodeling family
By extracting sleep data from two large and comprehensive ASD 
cohorts, combined with more detailed sleep phenotyping in a smaller 
cohort, we found that individuals with disruptive CHD8 and CHD7 
mutations show difficulties falling asleep and frequent and/or pro-
longed night awakenings, identifying specific problems in sleep main-
tenance. Despite sleep disturbances being one of the most prevalent 
complaints reported in CHD8 individuals (5, 8), it has been ques-
tioned whether the frequency of sleep defects is elevated over the 
already high prevalence associated with ASD (42) and thus whether 
CHD8 does play a specific role in sleep (9). Resolving various as-
pects of sleep disorders, we found sleep initiation and maintenance 
to be specifically enriched compared to idiopathic ASD, highlighting 
the importance of examining sleep defects with the greatest possible 
resolution. Moreover, using objective sleep assessment shows that 
the same complaints—short TST, low SE, and increased SOL and 
WASO—are present in individuals with mutations in its paralog 
CHD7, in accordance with previous CHARGE syndrome literature 
based on sleep questionnaires (3, 12, 13). These results must be in-
terpreted in the context of the limited cohort size that was available 
to us. Because of this limitation, it also remains to be determined 
whether sleep disturbance severity in individuals with CHD7 com-
pared to CHD8 mutations correlate with the overall more severe and 
broader clinical manifestation of CHARGE syndrome. However, the 
shared sleep characteristics of both disorders made them highly suit-
able for sleep studies in Drosophila with its single orthologous gene.
Similar to humans, we identified decreased and fragmented 
nighttime sleep in Drosophila kisk13416/+ mutants, denotating disturbed 
sleep maintenance. Although flies also sleep during the day, longer 
Fig. 7. Human CHD8 and CHD7 are highly expressed in glia and components of the BBB. (A and B) (Ai and Bi) CHD8 and (Aii and Bii) CHD7 expression in single-cell 
RNA-seq data of (A, Ai, and Aii) prenatal and (B to Bii) adult human cortex support a role for both kismet orthologs in glia throughout life span. Scatterplots after principal 
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sleep episodes preferentially occurring during the night are thought 
to reflect a crucial, deep sleep state (39). In kismet mutants, this dis-
ruption in sleep architecture results in decreased SE and increased 
night WASO, paralleling the sleep defects identified in individuals 
with mutations in CHD8/CHD7. Although sleep differences in the 
kismet mutant primarily rely on glial Kismet function, the absence 
of sleep phenotypes in pan-neuronal knockdown flies does not ex-
clude that Kismet may also modulate sleep through executing 
similar functions in neuronal entities regulating sleep. Considerable 
evidence suggests key roles for sleep in synaptic development and 
plasticity (43). Kismet has previously been shown to regulate syn-
apse assembly and synaptic transmission (18), and our findings es-
tablish a role for Kismet in sleep. Recent work in flies has likewise 
found that insomniac controls synaptic homeostasis in addition to 
its role in adult sleep (44). These results set the stage for investigat-
ing how sleep and synaptic functions are coupled at a genetic level. 
Our study reveals specific, highly conserved, and consistent defects 
in sleep maintenance caused by mutations in the CHD8/CHD7/
Kismet chromatin remodeling gene family.
Kismet and BBB glia play a role in sleep integrity, potential 
implications for individuals with CHD8/CHD7 mutations
Despite Kismet’s predominant expression in neurons (17, 18), we 
mapped its role in sleep to glia and more specifically to SPG, a key 
component of the Drosophila BBB. Thus, our data raise the intrigu-
ing possibility that glia and the BBB are involved in the patho-
physiology of the disorder. Despite only representing 2% of the glia 
population (29), kismet knockdown in SPG fully recapitulated pan-glial 
manipulations. Notably, this does not rule out that Kismet also 
operates in other glial subtypes to affect sleep. We observed mild but 
significant sleep fragmentation upon kismet knockdown in ALG and 
a decrease in sleep time upon EG manipulation. These additional 
roles of Kismet likely contribute to minor differences in phenotype 
between mutant, pan-glial, and SPG-specific phenotypes. We focused 
on the most marked and innovative phenotype and revealed that 
SPG dysregulation can give rise to reduced and fragmented sleep.
Inhibition of endocytosis in SPG and PG has recently been 
found to increase and consolidate sleep and to confer resistance to 
sleep deprivation (26). Our finding that sleep rebound remains in-
tact upon kismet knockdown and that its function is confined to 
SPG, not PG, suggests that SPG regulate different sleep processes 
through multiple mechanisms. Apart from sleep, it has been shown 
that the permeability of the Drosophila BBB is rhythmically con-
trolled by a molecular clock residing in PG (31). Whether Kismet 
loss also leads to changes in BBB permeability and how this relates 
to loss of CHD8 and/or CHD7 are exciting questions for future 
research, as emerging data suggest a potential connection of BBB 
changes to other dysregulated states, including epilepsy (45).
Notably, Kismet loss in SPG already disrupts sleep architecture 
in Drosophila larvae, resulting in shorter and more frequent bouts. 
Thus, our work reveals the importance of glia cells, specifically of 
SPG, in larval sleep and shows that Kismet’s function in sleep per-
sists from early development to adulthood. In contrast, classic 
short-sleeping mutants do not show larval sleep defects, and even a 
key regulator of arousal such as dopamine does not show the same 
waking effects in larvae as in adults (32). It is conceivable that 
Kismet’s function in glia and its persistent role in sleep throughout 
life span are directly related. SPG are specified during embryogenesis 
and maintain numbers and function from early larval specification 
to adulthood (30), while neurons undergo extensive remodeling 
during metamorphosis (46). Hence, SPG-encoded regulation of 
sleep may provide a mechanism for persistent sleep control across 
the life span.
Could dysregulation of the BBB contribute to CHD8- and CHD7- 
associated pathologies? Our single-cell expression analyses revealed 
that both genes are expressed in glia in prenatal and adult human 
cortex. Although the mature mammalian BBB is not exclusively 
constituted by glia cells, it shares many commonalities with the 
Drosophila BBB, including structural features, function, and regula-
tory mechanisms (45). However, in mammalian embryogenesis, the 
first cellular barrier separating the nervous system from the vascu-
lar elements is constituted by radial glia (47). Most relevantly, both 
CHD8 and CHD7 are expressed in prenatal endothelial and mural 
cells and in radial glia. Both genes are also highly expressed in the 
components of the mature BBB (astrocytes, endothelial cells, and 
pericytes). They are also highly expressed in oligodendrocyte pre-
cursor cells (OPCs) and oligodendrocytes, together supporting a 
sustained role of CHD8/7  in glia and previous findings in mouse 
that have revealed a key role for both genes in OPC survival and 
oligodendrocyte differentiation, myelination, and postinjury remy-
elination (48–50). On the basis of their expression and in light of the 
highly specific and conserved aspects of sleep that are affected in both 
species, it appears plausible that glia and/or other BBB-contributing 
cells, and a function of CHD8 and CHD7 therein, are relevant to the 
pathophysiology of these neurodevelopmental disorders.
Origin and consequences of hyperserotonemia caused by 
glial loss of Kismet
We found that glial loss of Kismet leads to increased levels of sero-
tonin, both in adults and in third instar larvae. Multiple studies have 
demonstrated elevated platelet serotonin in idiopathic ASD cohorts; 
this finding, referred to as hyperserotonemia, has proven to be one 
of the most replicated and consistent biomarkers in ASD (35, 36). 
However, despite ~60 years since the initial study reporting hyper-
serotonemia, its origin and role in ASD-associated clinical features 
have remained largely unsolved. Our study provides several im-
portant steps forward in this field. First, the genetic basis of hyper-
serotonemia in ASD has remained largely unknown (51). Our findings 
link hyperserotonemia to the evolutionary conserved CHD8/CHD7/ 
Kismet family, highly implicated in ASD (6, 7). Second, the etiology 
of sleep problems associated with autism is unclear; they have clas-
sically been regarded as secondary to other behavioral deficits (52). 
Moreover, whereas the involvement of serotonin in sleep regulation 
has been known for many years, it has remained unclear whether 
serotonin plays a sleep- or a wake-promoting effect (34, 53). Recent 
work has shown that acute activation of serotonergic neurons in 
Drosophila adults leads to sleep fragmentation without changing 
sleep duration (39), whereas we observed that serotonergic neuro-
nal activation during development (in second instar larvae) leads to 
a decrease in sleep amount and shorter sleep bouts. Together, these 
data suggest that the serotonergic regulation of sleep is neuronally 
mediated but context dependent (i.e., dependent on developmental 
stage and/or duration of serotonin dysregulation), which contributes 
to the complexity of serotonin’s role in sleep. Moreover, not unex-
pectedly, it appears to depend on the cell type of origin. Whereas 
we did not (yet) observe a change in total sleep amount in kismet 
knockdown L2 larvae, activation of serotonergic neurons at the same 
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due to a stronger activation of serotonergic neurons in the latter case. 
Despite this complexity, our multiple lines of evidence obtained 
through genetic, thermogenetic, and pharmacological manipula-
tions demonstrate that high serotonin levels during development 
cause sleep disturbances later in life and suggest hypersero-
tonemia as a sleep-relevant mechanism in individuals with muta-
tions in CHD8/7.
Last, increased serotonin has been associated with various ASD- 
relevant behaviors, including social behavior, in both patients and 
animal models (54, 55). Thus, our findings may account for other 
ASD-associated clinical features than just the sleep disturbances in 
individuals with CHD8/7 mutations. As we observed increased se-
rotonin levels in the projections to the proventriculum and anterior 
midgut, serotonin imbalance in these organs could contribute to 
other physiological and/or behavioral problems [e.g., gastrointesti-
nal problems reported in individuals with CHD8 mutations (5)]. In 
conclusion, our study establishes a causal relationship between BBB 
glia, hyperserotonemia, sleep, and one of the most frequent risk fac-
tors of ASD, providing substantial progress in autism research.
How does Kismet loss lead to hyperserotonemia? Although di-
rect target genes of Kismet in glia remain to be determined, a recent 
targeted DNA adenine methyltransferase identification (DamID) 
analysis in intestinal stem cells (56) identified four genes associated 
with the serotonergic system: the receptors 5-HT2A, 5-HT2B, and 
5-HT7 and AANAT1. Since we showed that increasing serotonin 
levels via AANAT1 knockdown in glia and SPG phenocopied the 
fragmented nighttime sleep observed in kismet knockdown, glial 
AANAT1 deregulation may account for or contribute to the observed 
sleep defects in the Drosophila models and participate in CHD8/CHD7 
pathophysiology. Human AANAT (homolog of AANAT1) is required 
for melatonin synthesis, and its activity is reduced in ASD cohorts 
(51), which additionally present with low plasma and urine mela-
tonin levels (57). Previous work has shown that AANAT1 mutants 
exhibit increased rebound upon sleep deprivation (58), and that 
astrocytic AANAT1 is crucial for proper homeostatic rebound, while 
its loss in neurons leads to a more consolidated sleep (59). Our 
work shows yet another previously unidentified and cell-specific 
role of AANAT1 in sleep regulation and is consistent with evidence 
for serotonergic regulation of sleep in Drosophila. Further work is 
needed to understand which dysregulated Kismet target genes in 
SPG lead to hyperserotonemia and how these findings may relate to 
human CHD8 and CHD7 pathology.
How does hyperserotonemia arising from Kismet dysfunction lead 
to sleep disturbances? Our data show that pharmacologically reduc-
ing serotonin levels in pan-glial kismet knockdown flies restores 
adult sleep integrity when applied during development. The fact that 
MTP treatment causes lethality in control animals with normal 
serotonin levels, but is not lethal in kismet knockdown larvae, fur-
ther supports a link between Kismet and developmentally increased 
serotonin. Reversely, pharmacologically increasing serotonin levels 
with 5-HTP in the same critical window lead to a decreased and 
fragmented sleep in wild-type flies. The effect of 5-HTP may not be 
as notable as kismet knockdown due to the light sensitivity of this 
compound as treated animals were kept at 12:12 LD. Moreover, it 
has been reported that during development, serotonin restricts the 
growth of serotonergic neurons via a negative feedback loop (60). 
Thus, increased serotonin levels upon Kismet loss during critical 
periods for circuit formation and maturation may lead to loss of 
serotonergic terminals and miswiring of neural networks, in analogy 
to existing prominent hypotheses how hyperserontonemia can cause 
ASD-associated clinical features (55).
Applicability of SRT in CHD8/7 syndromes and other 
neurodevelopmental disorders
The developmental trajectories of sleep disturbances in young chil-
dren with neurodevelopmental disorders suggest that we should 
instigate intervention as early as possible, yet there is an urgent need 
to remediate sleep problems in older children and adults as well. We 
show here that SRT improved sleep quality in both pan-glial and 
SPG kismet knockdown flies. With this behavioral approach, we ef-
fectively rescued shortened sleep bout duration and increased bout 
number, restored SE and WASO to control levels, and significantly 
improved sleep latency. Notably, these aberrancies in sleep metrics 
in Drosophila reflect those perturbed in CHD8 and CHD7 individu-
als. It is remarkable that sleep opportunity restriction, applied only 
in adulthood, can override sleep defects that are, as we demonstrated, 
of developmental origin. Hence, we propose that SRT provides a 
viable strategy to improve sleep in patients with CHD8/CHD7 mu-
tations and perhaps other forms of autism and related neurodevel-
opmental disorders. Although not quantitatively assessed, components 
of CBT-I including sleep opportunity restriction (i.e., shortening 
bedtimes) were advised to CHD8/7 individuals 01 to 04 seen in our 
sleep center and showed positive effects on the insomnia, as docu-
mented in the patient files (table S2).
In this study, we shed light onto mechanisms and cellular sub-
strates regulating sleep, linking the evolutionary CHD8/CHD7/
Kismet family to BBB glia, hyperserotonemia, and ASD-associated 
sleep defects. With our work, we also aim to contribute to a para-
digm shift away from the commonly held view that sleep deficits are 
coupled inevitably to the neurodevelopmental disorders in which 
they occur and are therefore refractory to therapy.
MATERIALS AND METHODS
Study design: Sleep assessment of CHD8 and CHD7 
individuals
In neurodevelopmental disorder cohorts, the prevalence of CHD8 
and CHD7 loss-of-function mutations lies in the range of 0.15 to 
0.40% and 0.28%, respectively (5, 61, 62). We assessed sleep charac-
teristics in a cohort of individuals with CHD8 mutations using 
structured questionnaires. Probands included 23 individuals with 
disruptive mutations to CHD8. Six individuals were drawn from the 
SSC (63, 64), and 17 probands were drawn from an ongoing study of 
individuals with mutations to ASD-associated genes (NIMH TIGER) 
(9). Pathogenic or likely pathogenic mutations to CHD8 were con-
firmed through review of clinical or research genetic testing results; 
individuals with other pathogenic mutations to neurodevelopmen-
tal disorder and/or sleep related genes were excluded from analyses. 
To establish a comparison group of individuals with ASD but no known 
genetic etiology (“idiopathic” ASD), 2305 probands without pathogenic 
ASD-associated single-gene variants or deleterious copy number 
variants as confirmed by whole-exome sequencing were drawn from 
the SSC (64, 65). Age and sex for the CHD8 group and the idiopath-
ic comparison group are presented in table S3. Written consent was 
obtained from participants, and all procedures were approved by 
the University of Washington Institutional Review Board.
A comprehensive, structured medical history interview initially 
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of all participants in SSC and NIMH TIGER, which included ques-
tions about history of sleep problems. Caregivers were asked wheth-
er their child had ever experienced the sleep problems listed in table 
S1, which included bedtime problems, excessive daytime sleepiness, 
sleep-disordered breathing, and nighttime awakenings. The same 
sleep history questions were used in both SSC and TIGER. Fisher’s 
exact tests were used to determine whether rates of specific sleep 
problems in individuals with disruptive CHD8 mutations differed 
from a large, idiopathic ASD group obtained through the SSC. 
Bonferroni correction for multiple comparisons was applied to the 
significance level (P < 0.005). Groups differed by gender [2(1, n = 
2311 = 9.84, P = 0.002)], with the CHD8 sample containing a signifi-
cantly larger proportion of females than the SSC group. Groups did 
not differ by age [t(22.19) = −1.52, P > 0.05]. Analyses were com-
pleted in SPSS version 26 (IBM Corp., 2019).
Second, to further address the clinical significance of CHD7/8- 
associated sleep problems, we searched for individuals with CHD7 
or CHD8 pathogenic mutations that have been seen in a tertiary 
sleep medicine center upon referral due to sleep complaints. There-
fore, we screened all referrals between 2012 and 2019 for individuals 
with mutations in those genes, identifying one additional individual 
with a pathogenic CHD8 mutation and three patients with CHD7 
mutations. All four patients underwent a basic clinical workup in-
cluding a full history taking, physical examination, and a consensus 
sleep diary (66), based on which time in bed (TIB), TST, SOL, WASO, 
and SE were calculated per individual with a 15-min bin resolution 
provided by the parent-reported sleep-wake calendars. SE was cal-
culated as TST divided by TIB and multiplied by 100. SOL was cal-
culated as the time between going to bed and sleep onset. WASO was 
calculated as the total time awake between sleep onset until the end of 
TIB. When appropriate, wrist actigraphy (MotionWatch 8, CamNtech, 
Cambridgeshire, UK) or video-PSG was performed. A sleep disor-
der diagnosis was made according to the ICSD-3 criteria (66, 67). 
Mean sleep duration was compared to values typically characteriz-
ing a pediatric population (68). Effective and ineffective treatments 
(pharmacological and behavioral) either received in the past or ap-
plied after consultation in the sleep clinic are reported in table S2. 
Informed consent was according to local ethical procedures.
Drosophila strains and husbandry
Fly stocks were reared on standard medium containing cornmeal, 
yeast, sugar, and agar at 25°C and 60% humidity in a 12:12 LD cycle. 
The following fly stocks were used for this study: iso31, kisk13416 mu-
tants [(Bloomington Drosophila Stock Center (BDSC) #10442)] 
backcrossed 6× to iso31, UAS-kisRNAi1 (VDRC #46685), UAS-kisRNAi2 
(VDRC #109414), UAS-AANAT1RNAi1 (VDRC #47906), UAS-AANAT1RNAi2 
(VDRC #105064), UAS-AANAT1RNAi3 (BDSC #36726), back-
ground control GD library [Vienna Drosophila Resource Center 
(VDRC#60000 )], background control KK library (VDRC #60.100), 
background control Transgenic RNAi Project (TRiP) library attP40 
(BDSC #36304), repo-Gal4 (UAS-Dcr2/CyO; repo-Gal4/TM3, Sb), 
repo-2-Gal4 (repo-Gal4/TM6b, Tb, Sb), repo-Gal4,tubGal80ts 
(repo-Gal4,tubGal80ts/TM3, Sb), elav-Gal4 (UAS-Dcr2; elav-Gal4), 
SPG-Gal4 (R54C07-Gal4, BDSC #50472), PG-Gal4 (R85G01-Gal4, 
BDSC #40436), ALG-Gal4 [NP3233-Gal4, [Drosophila Genomics 
Resource Center (DGRC) #113173], EG-Gal4 (NP6520-Gal4, DGRC 
#105240), CG-Gal4 (NP2222-Gal4, DGRC #112830), SPG-2-Gal4 
(NP2276-Gal4, DGRC #112853), Trh-Gal4(II) (BDSC #38388), 
Trh-Gal4(III) (BDSC #38389), and UAS-dTrpA1 backcrossed 6× to 
iso31. The UAS-kisRNAi1 line has previously been shown to induce a 
strong knockdown (≈90%) (17, 20). The pKC43 insertion sites of the 
KK RNAi lines used in this study were verified by diagnostic poly-
merase chain reaction according to the findings of Green and colleagues 
(69). The hairpin construct of the UAS-kisRNAi-2 line (VDRC #109414) 
was found to be inserted in both 40D and 30B landing sites, in 
agreement with information meanwhile available at VDRC. Thus, an 
additional control for the effect of the UAS insertion into the 40D 
locus was used (VDRC #60101), referred to as UAS-40D control.
Adult sleep analysis
Locomotor activity and sleep were recorded with the Drosophila 
Activity Monitor (DAM2) system from TriKinetics (Waltham, MA, 
USA). Briefly, 3- to 5-day-old male flies were individually transferred 
without CO2 anesthesia to glass tubes (65 mm by 5 mm) containing 
standard food, loaded into the DAM systems, allowed to acclima-
tize to activity monitors and food for at least 12 hours, and moni-
tored for 4 days at 25°C in a 12:12 LD cycle. For SRT experiments, 
the acclimation and monitoring were performed simultaneously in 
two different incubators at 12:12 LD and 14:10 LD. Motion was de-
tected via the monitors’ infrared light beams, and activity and sleep 
(defined in Drosophila as 5 or more minutes of inactivity) (58, 70) 
parameters were extracted from the beam breaks using the publicly 
available Sleep and Circadian Analysis MATLAB Program (71) for 
MATLAB. P(Wake) and P(Doze) were calculated from the two first 
days of activity monitoring recordings with the MATLAB scripts 
deposited in GitHub (23, 39). SE in Drosophila is depicted as time 
spent asleep divided by the opportunity window (ZT12 to ZT24 for 
flies entrained at 12:12 LD or ZT14 to ZT24 for flies entrained at 
14:10 LD). WASO was calculated by subtracting the latency to the 
first sleep episode from the total time spent awake during the dark 
period (ZT12 to ZT24 for flies entrained at 12:12 LD or ZT14 to ZT24 
for flies entrained at 14:10 LD). All sleep data are the average over 
the 4 days of data acquisition, except for SRT where data are the aver-
age of days 3 and 4 to allow entrainment to the new light regime.
Circadian analysis
Three- to five-day-old male flies were loaded into the DAM system 
as described above and entrained to a 12:12 LD cycle for 3 days be-
fore being transferred to constant darkness (DD). Locomotor ac-
tivity during days 2 to 7 in DD was analyzed in ClockLab software 
(Actimetrics, Wilmette, IL). FFT (72) was performed, and the max-
imum amplitude of the FFT was calculated and compared across 
genotypes. According to their FFT, flies were categorized as strongly 
rhythmic (FFT ≥ 0.05), moderately rhythmic (0.05 > FFT ≥ 0.03), 
weakly rhythmic (0.03 > FFT ≥ 0.01), or arrhythmic (FFT < 0.01).
TARGET system experiments
The temperature-dependent TARGET system (73) was used for tem-
poral mapping experiments. Flies were reared at either 22°C (restrictive 
temperature) or 28°C (permissive temperature) and, after eclosion 
(day 0), were either kept at the same temperature or swapped as 
indicated to confine gene knockdown to pre- or posteclosion periods. 
Genetic background controls were reared in parallel with the exper-
imental flies. All experiments were conducted in a 12:12 LD cycle.
Drug supplementation experiments
MPH (Brocacef, Maarssen) was supplemented in fly food at a final 
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MTP (Sigma-Aldrich, M8377) was diluted in fly food to achieve 
a final concentration of 20 mM (38). MTP was administered only 
during sleep monitoring for acute treatment, or only throughout 
development in 5 ml of food containing the drug (until DAM on 
vehicle food). 5-HTP (Sigma-Aldrich, H9772) was diluted in fly food 
to achieve a final concentration of 5  mM and administered only 
during development in 5 ml of food containing the drug, and adults 
after eclosion were reared and monitored on regular food. All drugs 
were dissolved in Milli-Q water.
Sleep deprivation
Flies in DAM2 monitors were placed on a TriKinetics vortexer mount-
ing plate (Waltham, MA, USA), and their activity was recorded for 
three consecutive days. On the second day, they were shaken for 2 s 
randomly within every 20-s window for 12 hours during the dark 
period (ZT12 to ZT24). The capability of each tested genotype to 
rebound was assessed by comparing the total sleep during ZT0 to 
ZT3 in the preceding day under unperturbed conditions (baseline) 
and the same time period following sleep deprivation (recovery).
Larval rearing and sleep assay
Experiments were carried out as previously described (32, 74). Briefly, 
to collect developmentally synchronized second instar larvae, adult 
flies were placed in an embryo collection chamber, kept at 12:12 LD 
and 25°C, and allowed to lay eggs on a petri dish containing 3% agar, 
2% sucrose, and 2.5% apple juice with yeast paste on top for 24 hours. 
Animals developed on this medium for 48 hours, after which late first 
instar larvae near ecdysis (based on the presence of double mouth 
hooks and double vertical plates) were collected. After they finished 
molting into second instars, single larvae were carefully transferred 
into LarvaLodge wells containing 100 ml of 3% agar and 2% sucrose 
medium covered with a thin layer of yeast paste. The LarvaLodge 
was covered with a transparent acrylic sheet and placed into a be-
havior room at 25°C and DD for imaging via infrared light. Notably, 
larval sleep is neither light- nor circadian-regulated (32). Time-
lapse images were acquired every 6 s with the software IC Capture 
(The Imaging Source). Images were analyzed using custom-written 
MATLAB software (74). The first hour of data acquisition was dis-
carded to allow acclimation. All data shown are the average of the 
4 hours following acclimation. For dTrpA1 activation experiments, 
embryo collection chambers were kept instead at 22°C and 12:12 
LD, and temperature was raised to 30°C during sleep recordings.
High-performance liquid chromatography
HPLC was used to quantify dopamine and serotonin levels in fly 
head extracts. Three- to 5-day-old male flies entrained in a 12:12 LD 
cycle were frozen by immersion in liquid nitrogen at ZT6 and ZT18 
after at least 24-hour recovery from CO2. Samples were acquired 
without disturbing the LD cycle. Fly heads were detached from their 
bodies by gentle vortexing. Per sample, three heads were transferred 
to an Eppendorf tube containing 100 l of ice-chilled 0.1 M perchlo-
ric acid (pH 3.0) and homogenized using a hand tissue grinder. Ho-
mogenates were kept on ice for 10 min to denaturalize the proteins, 
followed by centrifugation at 14,000  rpm for 15  min at 4°C. The 
supernatant was transferred to an Ultrafree-MC filter with a pore 
size of 0.45 m (Merck Millipore), filtered by centrifugation for 1 hour 
at 14,000 rpm at 4°C, and stored at −80°C until HPLC analysis. Ten 
microliters of the filtrate was analyzed using HPLC with electro-
chemical detection (EICOMPAK SC-30DS, EICOM) using a 
mobile phase consisting of 80% citrate-acetate buffer (0.1 M) (pH 
3.5), methanol (20%) with sodium octane sulfonate (220 mg/liter) 
and EDTA-2Na (5 mg/liter), pumped at a rate of 360 l/min through 
a 3.0 mm by 100 mm column (EICOMPAK SC-30DS, EICOM), as 
described by the manufacturer.
Immunohistochemistry, imaging, and quantification
Proventriculus and anterior midgut of male from wandering third 
instar larvae were dissected in phosphate-buffered saline (PBS) and 
immediately fixed in 4% paraformaldehyde dissolved in PBS for 
30 min at room temperature. Tissues were washed for 30 min with 
PBS with 0.6% Triton X-100 (PBST) and blocked for 2  hours at 
room temperature with 3% goat serum in PBST. Tissues were incu-
bated overnight at 4°C with primary antibody against serotonin 
(1:500; Sigma-Aldrich, S5545). Secondary donkey anti-rabbit antibody 
conjugated with Alexa Fluor 488 (1:1000; Thermo Fisher Scientific, 
A-21206) was incubated overnight at 4°C. Samples were then washed 
again five times in PBST and mounted in ProLong Gold Antifade 
Mountant (Thermo Fisher Scientific, P36930).
Samples were imaged using a Leica SP8 laser scanning confocal 
microscope with Hybrid Detector technology for quantitative im-
aging through single-photon counting. Images were analyzed using 
ImageJ to calculate the corrected total cell fluorescence (CTCF): 
CTCF = integrated density [corresponding to the sum of all pixel 
values the region of interest (ROI)] – (area ROI  ×  mean fluores-
cence of background readings), with ROIs being per image (i) the 
entire proventriculus and (ii) region of the anterior midgut. Two 
regions per image in the proventriculus not containing the proven-
tricular ganglion nor serotonergic innervation were selected, aver-
aged, and used to determine the mean fluorescence of background 
readings.
CHD8 and CHD7 expression in human cortex
The t-stochastic neighbor embedding projections along with the cluster 
annotations were retained from the original body of work for both 
the developing (75) and the adult cortex (76). The single-cell RNA-
seq counts per million for both datasets were processed into Unique 
molecular identifier (UMI) counts using quantile normalization 
(77) with the shape parameter set to “2.3.” SCTransform (78) was 
applied on the post quantile normalized count matrix. The plots for 
expression are the log-normalized expression corrected through 
SCTransform.
Statistical analysis
Adult and larval Drosophila sleep data statistical analysis was carried 
out in GraphPad Prism version 7 for Macbook (GraphPad Software, 
San Diego, CA, USA). Datasets of only two groups that followed a 
Gaussian distribution but showed differences in their standard de-
viation with the controls were analyzed with a two-tailed unpaired 
Welch’s t test. For groups of more than two genotypes, Kruskal- 
Wallis test with Dunn’s multiple comparisons test was performed to 
assess significance between the tested groups. Post hoc Bonferroni 
correction for multiple testing was further applied for the number 
of tests performed on a dataset per genotype to determine the cor-
rected two-sided significance level. Only P values that pass the cor-
rected significance level are indicated in the figures. All data shown 
are from at least three independent experiments (N  =  3) unless 
specified otherwise. For sleep deprivation experiments, statistical 
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baseline and recovery day per each genotype. Post hoc Bonferroni 
correction for multiple testing was further applied to correct for the 
number of tests performed on a dataset per genotype. Only P values 
that withstand multiple testing correction are indicated in the figures. 
At least three independent biological replicates were performed per 
genotype. Statistical significance of dopamine and serotonin levels 
was determined with a two-tailed unpaired t test between the tested 
groups of three independent biological replicates.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/23/eabe2626/DC1
View/request a protocol for this paper from Bio-protocol.
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